THERE ARE MULTIPLE WAYS TO MONITOR PROGRESSION OF BONE METASTATIC DISEASE

<table>
<thead>
<tr>
<th>MONITORING MODALITIES</th>
<th>CLINICAL CONSIDERATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PSA Testing</td>
<td>• Shown to be a predictor of disease progression and survival²</td>
</tr>
<tr>
<td></td>
<td>• Should be used with other disease progression indicators³</td>
</tr>
<tr>
<td>Radiographic Imaging</td>
<td>• Utilized to diagnose metastasis and to identify disease progression⁴,⁵</td>
</tr>
<tr>
<td></td>
<td>• Modalities can range in specificity and sensitivity⁴,⁵</td>
</tr>
<tr>
<td>Symptoms Assessment</td>
<td>• Multiple symptoms are associated with bone metastasis⁶</td>
</tr>
<tr>
<td></td>
<td>• Patients often underreport their symptoms⁶</td>
</tr>
</tbody>
</table>

• Include clinical symptoms when monitoring disease progression

PATIENTS WITH BONE METASTATIC DISEASE EXHIBIT A RANGE OF SYMPTOMS BEYOND PAIN

• Fatigue, generalized weakness⁷
• Interference with daily activities⁸

• Impaired mobility⁷
• Pain and discomfort⁷,⁸
• Interference with sleep⁸
• Loss of appetite⁹

• Neurologic impairment¹⁰
• Loss of bladder and bowel function⁷
• Pathological fracture¹¹
• Cord compression⁷

68% of patients ignore their symptoms; proactive discussion with your patients helps you evaluate progression of disease to determine therapeutic intervention⁶
In Advanced Prostate Cancer…
Symptoms Help Guide Your Clinical Approach¹

HOW DO YOU IDENTIFY PATIENTS WITH ADVANCING mCRPC?

Recently John has been cutting back on activities he enjoys, like going on outings with his family.

“I love my grandchildren, but I just don’t have the energy to keep up with them like I used to.”

In the last couple of weeks, Mike has been having difficulty climbing the stairs to his bedroom.

“It just hurts when I lift my legs up.”

Bill has lost 5 pounds since his last visit and his appetite is diminished.

“I feel fine but I really haven’t been hungry.”

Monitoring symptomatic progression is an important factor when considering your clinical approach in patients with advanced prostate cancer

mCRPC, metastatic castration-resistant prostate cancer; PSA, prostate-specific antigen.